Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical biotechnology company developing a new form of local immunotherapy termed “anchored immunotherapy,” today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US and Canada) to evaluate ANK-101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) following the completion of a first-in-human phase I study of ANK-101 alone in patients with advanced solid tumors.

Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Bristol-Myers

Johnson & Johnson

Eli Lilly

Major drugmakers including Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and Merck & Co Inc (NYSE:MRK) have agreed to participate in the Inflation Reduction Act's (IRA's) Medicare Drug Price Negotiation Program, the Biden administration said on Tuesday. The Inflation Reduction Act of 2022 granted the ability for Medicare to negotiate drug prices directly with manufacturers with the aim of reducing the costs of medications for seniors and other Medicare beneficiaries.

Drugmakers agree to participate in Medicare price negotiations

AbbVie

Amgen

Novartis

The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.

Drugmakers opt in to Medicare drug price negotiations – here's what happens next

The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.

FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease

AstraZeneca

Novo Nordisk

Pfizer

A federal judge dealt a blow to hopes for a near-term injunction to halt the federal government plan to let Medicare to pay less for a few expensive medicines.

Big Pharma Can't Stop the Price-Negotiation Program. What's Next.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet

Several major drugmakers, including Merck & Co. Inc. MRK and AstraZeneca PLC AZN, say they're moving forward with the Medicare drug-price negotiation process ahead of this Sunday's deadline to sign agreements to participate–but industry players are also waiting for a key legal ruling that could put the program on pause ahead of that date.

As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment

Merck said on Thursday the U.S. Food and Drug Administration (FDA) has accepted under priority review the company's application for an experimental therapy to treat pulmonary arterial hypertension (PAH) in adults.

Merck's blood vessel disorder therapy receives US FDA's priority review

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Priority Review from FDA for Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with PAH.

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

An antiviral drug that was granted an emergency use authorization by the U.S. Food and Drug Administration in December 2021 may be linked to mutations in the virus, according to a new study released on Monday.

Merck's COVID antiviral may be linked to virus mutations, study finds

A new study said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally spread to other people. But there is no evidence that molnupiravir, sold under the brand name Lagevrio, has produced more transmissible or severe variants of Covid, according to the study. The findings may increase scrutiny about the usefulness of the treatment, molnupiravir, which was one of the first Covid drugs available to doctors worldwide during the pandemic.

Merck Covid drug linked to virus mutations that can spread between people, new study says

Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.

Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies

Seagen

Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experimental bladder cancer medicine, Padcev, in combination with Merck's (MRK) Keytruda.

Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump

GlaxoSmithKline

Despite the increasing number of emerging challenges for the pharmaceutical industry, the management teams at GSK and Merck are successfully coping with them. GSK's revenue was $9.12 billion in the second quarter of 2023, up 8.1% year-over-year, beating analysts' estimates by $0.38 billion. Meanwhile, Merck's revenue continued to grow quarter over quarter and reached approximately $15.04 billion for the three months ended June 30, 2023.

Merck Vs. GSK: The Game-Changer Race In Pharma Excellence

Merck's crown jewel still sparkles, and that should continue for several years. The drugmaker is on the verge of earning approval for another blockbuster medicine.

3 Reasons to Buy Merck Stock

Merck and Japanese partner Eisai said Friday that two late-stage trials of a treatment for a certain type of non-small lung cancer failed to meet their primary goals in a disappointing outcome, but said they would continue to push ahead with their research.

Merck and Eisai say two lung-cancer trials failed to meet their main goals

Merck said on Friday its cancer immunotherapy Keytruda in combination with partner Eisai's drug failed to meet main goals in a late-stage study evaluating it as a treatment for patients with a type of lung cancer.

Drugmaker Merck says Keytruda combination fails in lung cancer trial

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA Plus LENVIMA in Patients With Certain Types of Metastatic NSCLC.

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of OS & PFS in Certain Patients With Previously Untreated la/m UC.

Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Keytruda is proving effective in treating more and more types of cancer, and its long-term growth potential is massive in my view. I believe Keytruda is set to generate $31 billion revenue by the end of 2025. Januvia/Janumet's fall should not be that sharp while Gardasil/Gardasil-9 is likely to continue to do well.

Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects

The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.

Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag

Merck & Co., Inc.'s payout ratios suggest that the market-beating dividend is well-covered. The company's stacked portfolio of therapies and candidates should lead to solid growth moving forward. My inputs into the discounted cash flows model show shares of Merck to be trading at a modest discount to fair value.

Merck: A Blue-Chip Dividend Stock Worth Buying

The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.

FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma

CRISPR Therapeutics

Molina Healthcare

UnitedHealth Group

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

Flee to Healthcare Stocks if Recession Rears its Head?

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Priority Review to Merck's Application for KEYTRUDA + Concurrent Chemoradiotherapy for Newly Diagnosed Locally Advanced Cervical Cancer.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

News for Merck Stock (MRK)